Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Publisher: La Merie Publishing
Format: Online and e-mail delivery
Product Code: LMDB0010
Release Date: November of 2016

7,000.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

A one-year subscription to this product provides 24/7 online access to both services from La Merie Publishing with a 30% discount on the list prices for all license types. Internet access is the only prerequisite for this service.

Upon purchse of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.

1) Flat-Rate Subscription to La Merie Publishing Reports & News Services

A one-year subscription to this service provides access to

  • all existing La Merie Publishing reports on stock and listed online in the store;
  • all new reports released by La Merie Publishing during the term of the subscription;

Among La Merie Publishing reports are:

A full listing of existing reports can be found in the online store. Publishing activities include updates of existing reports as well as release of new reports.

After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services, credentials to access a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.

Coverage of La Merie Publishing reports:
La Merie Publishing has a special focus on biologics including, but not limited to

  • Antibody-drug conjugates;
  • Bispecific antibodies including T-cell or NK cell redireting antibodies
  • CAR & TCR engineered T-cells and NK cells;
  • Immuno-oncology;
  • Biosimilar antibodies and proteins
  • Biosuperior antibodies;
  • Therapeutic proteins;
  • Therapeutic and prophylactic vaccines;
  • Therapeutic peptides.

Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced.

Full Reports and Brief Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.

Examples of Full Reports as of November 2016 are

  • TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs         
  • T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Examples of  Brief Reports as of November 2016 are

  • CD22: a suitable antigen for targeted payload delivery by immunotherapeutics  
  • CD123: a paradigmatic target for immunotherapeutic treatment modalities         
  • RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists         

Examples of Competitor Analysis Reports as of November 2016 are:

  • Biosimilar and Biosuperior Therapeutic Antibodies
  • PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
  • Bispecific Antibodies for Cancer, Inflammatory & Other Diseases          
  • PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

Examples of Vaccine Reports

  • Clostridium Difficile Vaccines and Therapeutics 2016
  • Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

Examples  of Peptide Reports

  • Cancer Peptides        
  • Cardiometabolic Peptides    
  • Anti-Infective Peptides        
  • Cardiovascular Peptides
  • Anti-Inflammatory Peptides


2) R&D Drug Pipeline Database: 1-Year Subscription

Subscription to La Merie Publishing’s proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development. Pre-established and free search functions allow to identify molecules according to their

  • Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)   
  • Technology (e.g. antibody-drug conjugate, bispecific antibody)
  • Target (e.g. Her2, Amyloid beta, TNF, PD-1/PD-L1)
  • Pipelines (selected by target, therapeutic area, company, technology)
  • Sales (for marketed antibodies, peptides and proteins)
  • R&D Phase (clinical phases, market, preclinical)
  • Territory (countrywise)
  • Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
  • Drug Code/Name (for individual molecules)

Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.

An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:

  • Antibodies
  • Proteins
  • Peptides
  • Vaccines

See our sample screenshots of the database: Download sample screenshots

Prerequisite: Internet access

Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the R&D Drug Pipeline Database:

  • Intuitive use
  • 24/7 online access
  • Designed for structured searches
  • Focused on targets, product categories and R&D phases
  • Ideal for competitor analysis (companies, targets, product categories)
  • Cost-effective and rapid solution for benchmarking
  • Identification of licensing candidates

Project listing in a tabular format:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Product Category
  • Company
  • Territory
  • Therapeutic Area
  • Indication
  • R&D Phase

Product Categories:

  • Antibody
  • Cell
  • DNA
  • Peptide
  • Protein
  • RNA
  • Small Molecule
  • Vaccine

Therapeutic Areas:

  • Cardiovascular, blood & acute care
  • Dermatology
  • Gastrointestinal
  • Genitourinary, gynecology & renal
  • Infectious & toxicology
  • Metabolism & endocrine
  • Neurology & psychiatry
  • Oncology
  • Ophthalmolgoy & otorhinolaryngology
  • Orthopedics, dental, anesthesia & surgery
  • Pulmonary & respiratory
  • Rheumatoid & autoimmune

Examples of Predefined Targets of the Scroll Down Menu:

  • Antibody-Drug Conjugates (ADC)
  • Sales of Antibodies & Proteins 2015
  • CAR & TCR Engineered T-Cells and NK Cells
  • Adalimumab (Humira) Biosimilars
  • Her2 Antibodies
  • Amyloid beta-Targeted Antibodies
  • CD10-Targeted Immunotherapeutics
  • Immunocytokines
  • Bispecific Antibodies
  • Peptide Sales 2015
  • PD-1 & PD-L1 Immune Checkpoint Inhibitors
  • Zika Virus Vaccines
  • Coagulation Factors
  • Botulinum Neurotoxins
  • Human Papilloma Virus (HPV) Vaccines & Therapeutics
  • G-CSF & GM-CSF
  • PTH-R Agonists
  • Cardiometabolic Peptides
  • Immune Checkpoint Modulators

Examples of Predefined Technologies of the Scroll Down Menu:

  • Transgenic XenoMouse Antibodies
  • T-Cell Redirecting Bispecific Antibodies
  • ADC - Pyrrolobenzodiazepine (PBD)
  • Fc-Fusion Proteins
  • Oligo- and Polyclonal Antibodies

Download Screenshots

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up